Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with ...

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Ublituximab shows five year relapse reduction and disability benefits in multiple sclerosis, supporting early high efficacy treatment strategies today.

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

From baseline to week 12 the adjusted mean difference in Modified Fatigue Impact Scale change was 1.88 and 1.20 for CBT and modafinil, respectively, relative to the combination group. HealthDay News — ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...